A vaccine developed in Japan aimed at preventing the lethal Nipah virus infection is progressing towards clinical trials, with plans to start these trials in April in Belgium. The project is being spearheaded by SCARDA (Strategic Center for Advanced Research and Development of Vaccine), which plays a critical role in domestic vaccine development.

The vaccine employs a viral vector approach, incorporating Nipah virus genes into a weakened form of the measles virus. This method is intended to induce the production of specific proteins associated with the Nipah virus, prompting an immune response that prepares the body to fend off actual infection by the virus. The measles virus is known for eliciting a strong and lifelong immune response, making it an effective component for this vaccine.

The impending clinical trials not only signify a major step in addressing Nipah virus threats but also highlight Japan's contributions to global health initiatives. If successful, this vaccine could significantly reduce the risk of Nipah virus outbreaks, which are characterized by high mortality rates and have previously caused severe health crises in affected regions.